{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:41:23Z","timestamp":1789735283324,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several MRI contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain, bones, and other organs of patients. This persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered Gd-based contrast agents (GBCAs) for MRI, prompting the European Medicines Agency to recommend discontinuing the use of over half of the GBCAs currently approved for clinical applications. To address this problem, we find that the orally-available metal decorporation agent 3,4,3-LI(1,2-HOPO) demonstrates superior efficacy at chelating and removing Gd from the body compared to diethylenetriaminepentaacetic acid, a ligand commonly used in the United States in the GBCA Gadopentetate (Magnevist). Using the radiotracer <jats:sup>153<\/jats:sup>Gd to obtain precise biodistribution data, the results herein, supported by speciation simulations, suggest that the prophylactic or post-hoc therapeutic use of 3,4,3-LI(1,2-HOPO) may provide a means to mitigate Gd retention in patients requiring contrast-enhanced MRI.<\/jats:p>","DOI":"10.1038\/s41598-018-22511-6","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T10:55:21Z","timestamp":1520420121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents"],"prefix":"10.1038","volume":"8","author":[{"given":"Julian A.","family":"Rees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier J.-P.","family":"Deblonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-6735","authenticated-orcid":false,"given":"Dahlia D.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ansoborlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey S.","family":"Gauny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"22511_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.mri.2016.08.017","volume":"34","author":"E Kanal","year":"2016","unstructured":"Kanal, E. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience. Magnetic Resonance Imaging 34, 1341\u20131345 (2016).","journal-title":"Magnetic Resonance Imaging"},{"key":"22511_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2214\/AJR.06.1094","volume":"188","author":"DR Broome","year":"2007","unstructured":"Broome, D. R. et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. American Journal of Roentgenology 188, 586\u2013592 (2007).","journal-title":"American Journal of Roentgenology"},{"key":"22511_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2015142690","volume":"276","author":"T Kanda","year":"2015","unstructured":"Kanda, T. et al. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology 276, 228\u201332 (2015).","journal-title":"Radiology"},{"key":"22511_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","volume":"43","author":"T Frenzel","year":"2008","unstructured":"Frenzel, T., Lengsfeld, P., Schirmer, H., H\u00fctter, J. & Weinmann, H. J. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investigative radiology 43, 817\u2013828 (2008).","journal-title":"Investigative radiology"},{"key":"22511_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.HP.0000326345.41816.c2","volume":"95","author":"PW Durbin","year":"2008","unstructured":"Durbin, P. W. & Lauriston, S. Taylor Lecture: the quest for therapeutic actinide chelators. Health physics 95, 465\u201392 (2008).","journal-title":"Health physics"},{"key":"22511_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3109\/02841851.2010.515614","volume":"51","author":"D Xia","year":"2010","unstructured":"Xia, D., Davis, R. L., Crawford, J. A. & Abraham, J. L. Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta radiologica (Stockholm, Sweden: 1987) 51, 1126\u201336 (2010).","journal-title":"Acta radiologica (Stockholm, Sweden: 1987)"},{"key":"22511_CR7","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1039\/c1dt10840a","volume":"40","author":"M Sturzbecher-Hoehne","year":"2011","unstructured":"Sturzbecher-Hoehne, M. et al. 3,4,3-LI(1,2-HOPO): In vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation. Dalton Transactions 40, 8340 (2011).","journal-title":"Dalton Transactions"},{"key":"22511_CR8","first-page":"11","volume":"31","author":"DL White","year":"1988","unstructured":"White, D. L., Durbin, P. W., Jeung, N. & Raymond, K. N. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. Journal of Medicinal Chemistry 31, 11\u201318 (1988).","journal-title":"Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands. Journal of Medicinal Chemistry"},{"key":"22511_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/HP.0b013e3181c21273","volume":"99","author":"RJ Abergel","year":"2010","unstructured":"Abergel, R. J. et al. Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Physics 99, 401\u2013407 (2010).","journal-title":"Health Physics"},{"key":"22511_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/095530000138853","volume":"76","author":"PW Durbin","year":"2000","unstructured":"Durbin, P. W., Kullgren, B., Xu, J. & Raymond, K. N. Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. International journal of radiation biology 76, 199\u2013214 (2000).","journal-title":"International journal of radiation biology"},{"key":"22511_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10534-016-9931-7","volume":"29","author":"M Rogosnitzky","year":"2016","unstructured":"Rogosnitzky, M. & Branch, S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. BioMetals 29, 365\u2013376 (2016).","journal-title":"BioMetals"},{"key":"22511_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","volume":"41","author":"GW White","year":"2006","unstructured":"White, G. W., Gibby, W. A. & Tweedle, M. F. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy. Invest Radiol. 41, 272\u2013278 (2006).","journal-title":"Invest Radiol."},{"key":"22511_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.mri.2016.08.016","volume":"34","author":"S Swaminathan","year":"2016","unstructured":"Swaminathan, S. Gadolinium toxicity: Iron and ferroportin as central targets. Magnetic Resonance Imaging 34, 1373\u20131376 (2016).","journal-title":"Magnetic Resonance Imaging"},{"key":"22511_CR14","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"P Marckmann","year":"2006","unstructured":"Marckmann, P. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. Journal of the American Society of Nephrology 17, 2359\u20132362 (2006).","journal-title":"Journal of the American Society of Nephrology"},{"key":"22511_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","volume":"51","author":"E Lancelot","year":"2016","unstructured":"Lancelot, E. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents. Investigative Radiology 51, 691\u2013700 (2016).","journal-title":"Investigative Radiology"},{"key":"22511_CR16","first-page":"1","volume":"00","author":"N Murata","year":"2016","unstructured":"Murata, N. et al. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue. Investigative Radiology 00, 1 (2016).","journal-title":"Investigative Radiology"},{"key":"22511_CR17","first-page":"150025","volume":"000","author":"RJ McDonald","year":"2015","unstructured":"McDonald, R. J. et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 000, 150025 (2015).","journal-title":"Radiology"},{"key":"22511_CR18","doi-asserted-by":"publisher","first-page":"150337","DOI":"10.1148\/radiol.2015150337","volume":"275","author":"A Radbruch","year":"2015","unstructured":"Radbruch, A. et al. Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent. Radiology 275, 150337 (2015).","journal-title":"Radiology"},{"key":"22511_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1667\/RR3115.1","volume":"179","author":"DI Bunin","year":"2013","unstructured":"Bunin, D. I. et al. Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. Radiation research 179, 171\u201382 (2013).","journal-title":"Radiation research"},{"key":"22511_CR20","unstructured":"Administration, U. F. & Drug. FDA Guidance. Tech. Rep., USFDA, Rockville, MD (2005)."},{"key":"22511_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3109\/09553002.2014.925150","volume":"90","author":"DD An","year":"2014","unstructured":"An, D. D. et al. 238Pu elimination profiles after delayed treatment with 3,4,3-LI (1,2-HOPO) in female and male Swiss-Webster mice. International Journal of Radiation Biology 90, 1055\u20131061 (2014).","journal-title":"International Journal of Radiation Biology"},{"key":"22511_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cbi.2016.03.034","volume":"267","author":"DD An","year":"2017","unstructured":"An, D. D., Kullgren, B., Jarvis, E. E. & Abergel, R. J. From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents. Chemico-Biological Interactions 267, 80\u201388 (2017).","journal-title":"Chemico-Biological Interactions"},{"key":"22511_CR23","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.mri.2016.08.018","volume":"34","author":"JP Prybylski","year":"2016","unstructured":"Prybylski, J. P., Maxwell, E., Coste Sanchez, C. & Jay, M. Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood\u2013brain barrier. Magnetic Resonance Imaging 34, 1366\u20131372 (2016).","journal-title":"Magnetic Resonance Imaging"},{"key":"22511_CR24","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1093\/ndt\/gfr085","volume":"26","author":"S Sanyal","year":"2011","unstructured":"Sanyal, S., Marckmann, P., Scherer, S. & Abraham, J. L. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis - An autopsy-based review. Nephrology Dialysis Transplantation 26, 3616\u20133626 (2011).","journal-title":"Nephrology Dialysis Transplantation"},{"key":"22511_CR25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/jmri.21966","volume":"30","author":"AD Sherry","year":"2009","unstructured":"Sherry, A. D., Caravan, P. & Lenkinski, R. E. Primer on gadolinium chemistry. Journal of Magnetic Resonance Imaging 30, 1240\u20131248 (2009).","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"22511_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1021\/ic00032a034","volume":"31","author":"X Wang","year":"1992","unstructured":"Wang, X. et al. A Kinetic Investigation of the Lanthanide DOTA Chelates. Stability and Rates of Formation and of Dissociation of a Macrocyclic Gadolinium(III) Polyaza Polycarboxylic MRI Contrast Agent. Inorganic Chemistry 31, 1095\u20131099 (1992).","journal-title":"Inorganic Chemistry"},{"key":"22511_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1039\/c3mt20237b","volume":"5","author":"GJ-P Deblonde","year":"2013","unstructured":"Deblonde, G. J.-P., Sturzbecher-Hoehne, M., Mason, A. B. & Abergel, R. J. Receptor recognition of transferrin bound to lanthanides and actinides: a discriminating step in cellular acquisition of f-block metals. Metallomics 5, 619 (2013).","journal-title":"Metallomics"},{"key":"22511_CR28","doi-asserted-by":"crossref","unstructured":"Sillanpaa, M. Environmental Fate of EDTA and DTPA. 85\u2013111 (Springer, New York, NY, 1997).","DOI":"10.1007\/978-1-4612-1964-4_3"},{"key":"22511_CR29","doi-asserted-by":"publisher","first-page":"10868","DOI":"10.1021\/ic9013703","volume":"48","author":"RJ Abergel","year":"2009","unstructured":"Abergel, R. J., D\u2019Aleo, A., Ng Pak Leung, C., Shuh, D. K. & Raymond, K. N. Using the Antenna Effect as a Spectroscopic Tool: Photophysics and Solution Thermodynamics of the Model Luminescent Hydroxypyridonate Complex [Eu III (3,4,3-LI(1,2-HOPO))]. Inorganic Chemistry 48, 10868\u201310870 (2009).","journal-title":"Inorganic Chemistry"},{"key":"22511_CR30","unstructured":"Abergel, R. & Deblonde, G. Formulations and treatments employing hydroxypyridonate actinide\/lanthanide decorporation agents (2017)."},{"key":"22511_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ddr.21246","volume":"76","author":"TA Choi","year":"2015","unstructured":"Choi, T. A. et al. Biodistribution of the Multidentate Hydroxypyridinonate Ligand [14\u2009C]-3,4,3-LI(1,2-HOPO), a Potent Actinide Decorporation Agent. Drug Development Research 76, 107\u2013122 (2015).","journal-title":"Drug Development Research"},{"key":"22511_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00004032-199210000-00007","volume":"63","author":"PW Durbin","year":"1992","unstructured":"Durbin, P. W., Jeung, N., Kullgren, B. & Clemons, G. K. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health physics 63, 427\u201342 (1992).","journal-title":"Health physics"},{"key":"22511_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/rpd\/53.1-4.305","volume":"53","author":"P Durbin","year":"1994","unstructured":"Durbin, P., Kullgren, B., Xu, J. & Raymond, K. In Vivo Chelation of Am(III), Pu(IV), Np(V), and U(VI) in Mice by TREN-(Me-3,2-HOPO). Radiation Protection Dosimetry 53, 305\u2013309 (1994).","journal-title":"Radiation Protection Dosimetry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22511-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:19:15Z","timestamp":1671592755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22511"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22511-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"assertion":[{"value":"29 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.A. and G.J.P.D are listed as inventors on two separate patent applications filed by the Lawrence Berkeley National Laboratory and describing inventions related to the research results presented here.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4419"}}